ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*purified enzyme, spectrophotometrical assay#organism*Staphylococcus epidermidis#literature*643964#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*cloning and characterization of staphopain A2 and its inhibitor from a novel staphylococcal thiol protease operon (stpAB2CH-91), staphopain/staphostatin interaction and evolution of encoding operons analyzed, evidence of ancestral allelic duplication and parallel evolution of the protease/inhibitor pairs suggested#organism*Staphylococcus aureus#literature*683202#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*staphopain A of Staphylococcus epidermidis used for assessment of staphopain-staphostatin interactions, kinetics shown#organism*Staphylococcus epidermidis#literature*683202#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*ability of staphostatins to form a complex with the active site mutant C21A of Staphylococcus warneri staphopain determined by size exclusion chromatography#organism*Staphylococcus warneri#literature*683202#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*cystatin C assay to analyze the disturbance of the host protease-inhibitor balance by bacterial staphopains described, enzyme kinetic parameters shown; MALDI-TOF based time-course experiments of cleavage of cystatin C and D by staphopain A indicated, cystatin C assay to analyze the disturbance of the host protease-inhibitor balance by staphopain A described, enzyme kinetic parameters shown#organism*Staphylococcus aureus#literature*683205#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*proteolytic cleavage of the C-terminus of chemerin, the tazarotene-induced gene 2 protein TIG2, by staphopain B determined by SDS-PAGE, HPLC-analysis and MALDI-TOF, cell-activating potential of chemerin cleavage products determined, clinical isolates of Staphylococcus aureus shown to activate chemerin, activation determined in the presence of plasma inhibitors, no activation of chemerin by staphopain B mutants observed#organism*Staphylococcus aureus#literature*683735#!ecNumber*3.4.22.48#specificActivity*-999#specificActivityMaximum*#commentary*peripheral blood neutrophils and monocytes exposed to SspB are extensively phagocytosed by resting human monocyte-derived macrophages in a time- and concentration-dependent manner. SspB-treated neutrophils engulfed in phagosomesstill preserve mitochondrial potential. SspB blocks phagocytosis of opsonised Staphylococcus aureus by neutrophils and monocytes. SspB blocks the chemotactic activity of neutrophils. SspB decreases surface expression of the major repulsion signal CD31 on neutrophils both in the absence and presence of human serum.#organism*Staphylococcus aureus#literature*696543#